Sarepta Therapeutics (AB3A) Stock Overview
A commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
AB3A Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Sarepta Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$14.54 |
| 52 Week High | US$37.90 |
| 52 Week Low | US$8.96 |
| Beta | 0.25 |
| 1 Month Change | -17.67% |
| 3 Month Change | -7.42% |
| 1 Year Change | -57.47% |
| 3 Year Change | -87.84% |
| 5 Year Change | -76.85% |
| Change since IPO | 62.64% |
Recent News & Updates
Recent updates
Shareholder Returns
| AB3A | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -8.6% | 0.9% | 3.2% |
| 1Y | -57.5% | -12.2% | 2.5% |
Return vs Industry: AB3A underperformed the German Biotechs industry which returned -11.9% over the past year.
Return vs Market: AB3A underperformed the German Market which returned 0.2% over the past year.
Price Volatility
| AB3A volatility | |
|---|---|
| AB3A Average Weekly Movement | 12.8% |
| Biotechs Industry Average Movement | 8.7% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in DE Market | 13.6% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: AB3A's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: AB3A's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1980 | 835 | Doug Ingram | www.sarepta.com |
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials.
Sarepta Therapeutics, Inc. Fundamentals Summary
| AB3A fundamental statistics | |
|---|---|
| Market cap | €1.54b |
| Earnings (TTM) | €56.05m |
| Revenue (TTM) | €1.88b |
Is AB3A overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AB3A income statement (TTM) | |
|---|---|
| Revenue | US$2.18b |
| Cost of Revenue | US$2.33b |
| Gross Profit | -US$141.65m |
| Other Expenses | -US$206.71m |
| Earnings | US$65.06m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.62 |
| Gross Margin | -6.49% |
| Net Profit Margin | 2.98% |
| Debt/Equity Ratio | 55.7% |
How did AB3A perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/22 15:03 |
| End of Day Share Price | 2026/05/22 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sarepta Therapeutics, Inc. is covered by 50 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Skorney | Baird |
| Huidong Wang | Barclays |
| Eliana Merle | Barclays |